Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HIKAL.NS
BuyHot AirHikal Limited · Healthcare · India · $320M · Avg Vol: $6M/d
75
StockRankGet insider-trade alerts
Q
49
V
39
M
82
P/E (TTM)
—
ROE
-4.1%
D/E
0.6x
Dividend %
0.2%
COMPANY DESCRIPTION
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals industries.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.0B | 17.7B | 18.4B | 17.0B | -5.4% | 12.0B | 18.8B | 21.4B | 12.4% |
| EPS (INR) | 6.36 | 5.64 | 7.36 | -3.96 | 7.6% | -2.73 | — | — | — |
| Shares | 123.3M | 123.3M | 123.3M | 123.3M | 0.0% | 123.3M | — | — | — |
| Debt | 7.5B | 8.2B | 7.6B | 6.8B | -3.0% | 6.8B | — | — | — |
| Equity | 11.3B | 11.9B | 12.6B | 12.0B | 1.9% | — | — | — | — |
| Op CF | 3.2B | 1.9B | 2.8B | 3.0B | -1.4% | 3.0B | — | — | — |
| Inv CF | -2.9B | -1.7B | -1.4B | -1.5B | — | — | — | — | — |
| Fin CF | -76.8M | -270.0M | -1.4B | -1.6B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+11.1%
SMA 50SMA 200
Close
$2.53
RSI (14)
63.2
52W High
$2.96
From 52W High
0.9%
SCORE BREAKDOWN
Quality
49
ROIC
0.1%44.8
ROE
-4.1%40.1
GP/Assets
23.9%52.0
Op. Margin
13.2%70.5
FCF/Assets
6.5%76.1
Piotroski
549.3
Int. Cover
0.0x35.9
D/E Ratio
0.57x26.2
Current Ratio
1.30x20.2
Value
39
P/E (TTM)
—N/A
EV/EBITDA
25.0x26.8
P/FCF
19.8x63.2
P/B
2.5x53.9
P/S
2.5x62.7
Div Yield
0.2%6.7
Momentum
82
52W High %
85%76.1
RS 6M
38%88.1
SMA 50/200
1.07x71.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+430%95.1
Q Growth
68%79.1
FUNDAMENTALS
Market Cap
$320M
P/E (Forward)
26.7x
Gross Margin
47.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HIKAL.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HIKAL.NS | Hikal Limited(you) | $320M | 75 | Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited | $356M | 81 | Strong Buy |
| AARTIDRUGS.NS | Aarti Drugs Limited | $406M | 80 | Strong Buy |
| BETA.NS | Beta Drugs Limited | $228M | 72 | Buy |
| RPGLIFE.NS | RPG Life Sciences Limited | $489M | 79 | Buy |
| GUFICBIO.NS | Gufic Biosciences Limited | $466M | 71 | Buy |
| FDC.NS | FDC Limited | $594M | 76 | Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%